Investors

Invest with confidence in the most promising ventures

Investors in UK Life Sciences want to fund innovators that can deliver outstanding returns for them and for patients.

But backing breakthroughs can mean sifting through high volumes of complex science in a broad and fragmented market to find those opportunities with the greatest potential. In an already high-risk market, many investors are choosing to withhold their money, rather than invest.

That is where we come in. We are a new early-stage venture fund founded on a promise made by Medicines Discovery Catapult (MDC) to channel its earnings for reinvestment to build a stronger UK Life Sciences sector. We are uniquely placed to do this thanks to our capital, our market-driven insight, and our ability to leverage the exceptional people and technologies within MDC.

Our goal is to find the most promising ventures and make them ‘fit-to-fund’. We do this by tracking national demand signals and then identifying the ideas and people to match them. We use our national view on the sector and our deep industrial and scientific due diligence to assess the potential of the idea, enhance the quality of the plan, and enable investment. We then provide the capital or counsel needed to help these innovators move closer towards translation.

Our approach gives investors confidence that every deal we back is grounded in real-world need and a credible route to greater impact.

This is not just about funding ideas, it’s about improving how value flows through our sector.

We back breakthroughs for healthier returns. Partnering with us can help de-risk your next investment and ensure your capital makes the greatest difference to you, to innovators, to the sector and to patients.